Bausch + Lomb (BLCO) has been in focus after third quarter results showed revenue of US$1.375b and net income of US$32 million, alongside a modest increase to full year 2026 revenue guidance.
Bausch + Lomb’s recent guidance tweak and return to quarterly profitability have come alongside a clear shift in sentiment, with a 30 day share price return of 15.28% and a 90 day gain of 19.13% feeding into a 1 year total shareholder return of 28.55%. This points to momentum building rather than fading around the US$19.99 share price as investors reassess both growth prospects and perceived risk after the latest results and board change.
Capitalize on the momentum around Bausch + Lomb by scanning a hand picked set of 19 high quality undiscovered gems that also pair improving fundamentals with active investor interest.After a 28.55% one year total return and a swing back to quarterly profit, Bausch + Lomb now asks a simple question of new money: Does the current valuation still leave enough upside to justify the risk?
Most Popular Narrative: 5.5% Undervalued
Compared with Bausch + Lomb’s last close of $19.99, the most followed narrative pegs fair value near $21.14. An 8.49% discount rate anchors that view and ties upside to specific product and margin levers rather than broad sector optimism.
The analysts have a consensus price target of $21.14 for Bausch + Lomb based on their expectations of its future earnings growth, profit margins and other risk factors.
Given the current share price of $20.4, the analyst price target of $21.14 is 3.5% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
See why 3 investors see Bausch + Lomb as 5% undervalued.
Result: Fair Value of $21.14 (UNDERVALUED)
Still, the Bausch + Lomb story can break if expected margin gains or late stage eye care trials stumble, which would challenge the current fair value narrative.
Find out about the key risks to this Bausch + Lomb narrative.
Next Steps
If this mix of renewed optimism and clear risk flags around Bausch + Lomb feels familiar, do not sit on the sidelines and let others frame the story for you. Weigh the upside against the concern points and check the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Bausch + Lomb?
If Bausch + Lomb has your attention, you can broaden your watchlist by scanning fresh opportunities that pair fundamental strength with clear, data backed signals across different styles.
- Target potential mispricing by reviewing companies flagged as high quality and potentially undervalued through the 39 high quality undervalued stocks.
- Prioritise resilience by checking out a list of solid balance sheet and fundamentals (24 results) that can help you focus on financially robust businesses when markets turn choppy.
- Lean into consistency by scanning a 29 resilient stocks with low risk scores that highlights stocks with steadier profiles instead of leaving your next idea to chance.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com